The ability of triple-helical collagen molecules to assemble into supramolecular structures forms the basis of commercial uses of collagen in the food industry and in medical applications such as cosmetic surgery and tissue repair. We have used cDNA techniques to engineer novel collagens with potentially enhanced biological properties ; however, expression of fully functional novel molecules is difficult due to the complex nature of procollagen biosynthesis. This article outlines the application of various expression systems to procollagen production and details the use of the mammary gland as a suitable bioreactor for the synthesis of significant amounts of novel procollagens from cDNA constructs.
Introduction
The ability of proteins to self assemble into macromolecules is fundamental to all living organisms. Some of the largest and most complex of these structures are the fibrils formed from the triple-helical protein collagen [l]. The fibrils are the main constituents of the extracellular matrix that underpins tissue assembly. Collagen and gelatine (denatured collagen) are used commercially to form gelling agents in the food industry, bulking agents in cosmetics and in corrective surgery, and to assemble artificial matrices to support cell growth during tissue repair. These industrial and medical uses are restricted to the type and availability of collagen molecules found naturally. We have developed the technology to construct collagen molecules with novel chain compositions and domain modifications that potentially will have enhanced biological properties. The only way of producing such engineered collagen molecules will be by recombinant technology.
Gly-X-Y triplet, where X and Y can be any amino acid but are frequently the imino acids proline and hydroxyproline. An important feature of fibrilforming collagens is that they are synthesized as precursor procollagens containing globular N-and C-terminal extension propeptides. The biosynthesis of procollagen is a complex process involving a number of different post-translational Initial stages in the folding and assembly of procollagen Three distinct stages can be defined in the folding and assembly pathway of procollagen. The first stage is the folding of the Cpropeptide, giving rise t o a globular domain. Three C-propeptides can then associate during the second stage t o form trimers. This association allows the third stage to occur, i.e. nucleation of the Gly-X-Y repeat region and folding ofthe triple-helical domain. The triple-helical structure is stabilized by post-translational modification of proline residues t o hydroxyproline. including proline and lysine hydroxylation, N-linked and 0-linked glycosylation and both intra-and inter-chain disulphide-bond formation. The enzymes carrying out these modifications act in a co-ordinated fashion to ensure the folding and assembly of a correctly aligned and thermally stable triple-helical molecule [2] . Procollagen folds and assembles through a series of distinct intermediates that can be characterized by their extent of modification, disulphide-bonding status and polymeric state ( Figure 1 ). As the polypeptide chain is co-translationally translocated across the membrane of the endoplasmic reticulum, hydroxylation of proline and lysine residues occurs within the Gly-X-Y repeat region [3] . Once the polypeptide chain is fully translocated into the lumen of the endoplasmic reticulum the C-propeptide folds [4] . Three proa chains then associate via their C-propeptides to form a trimeric molecule allowing the Gly-X-Y repeat region to form a nucleation point at its Cterminal end, ensuring correct alignment of the chains. The Gly-X-Y region then folds in a C-to-N direction to form a triple helix. The temporal relationship between polypeptide chain modification and triple-helix formation is crucial as hydroxylation of proline residues is required to ensure stability of the triple helix at body temperature [S], and once formed the triple helix no longer serves as a substrate for the hydroxylation enzyme [6] . The C-propeptides (and to a lesser extent the N-propeptides) keep the procollagen soluble during its passage through the cell. Removal of the propeptides by procollagen N-and C-proteinases lowers the solubility of procollagen by > 10000-fold and is necessary and sufficient to initiate the self-assembly of collagen into fibres [7] . Crucial to this assembly process are short nontriple-helical peptides called telopeptides at the ends of the triple-helical domain, which ensure correct registration of the collagen molecules within the fibril structure and lower the critical concentration for self-assembly [8].
Recombinant expression systems
Synthesis of recombinant collagen presents various problems, not least because of the many posttranslational modifications (some of which are unique to collagens) required for an expressed collagen molecule to achieve a fully folded, triplehelical conformation. Eight specific enzymic activities are required [l] and of these the modification carried out by prolyl4-hydroxylase (P4H ; reviewed in [3] ) is critical for triple-helix stability. Hence, traditional high-yield expression systems such as bacteria and yeast that do not contain any P4H activity have not been used for collagen production without modification of the host. By co-expressing recombinant type-111 procollagen together with mammalian P4H in the yeast Pichiu pustoris, it has recently been demonstrated that triple-helical procollagen (the soluble precursor of collagen containing N-and C-propeptides) can be produced [9] . Similarly, although insect cells possess a very low level of endogenous P4H activity, co-transfection of such cells with a combination of baculovirus vectors encoding human type-I11 procollagen and both a-and 8-subunits of P4H yielded up to 60 pg/ml cellular procollagen [lo] . However, when expressed in yeast or insect cells, the protein is not secreted and must be extracted from the cells by treatment with pepsin, a protease that does not digest the triple-helical domain but does damage the telopeptides. As a consequence, pepsin-extracted collagen is unable to form ordered fibrillar structures [8] . Mammalian cell lines that possess adequate levels of endogenous P4H have also been used to express procollagens. Yields vary between the type of cell line used and the expression vector and range from relatively low levels using the HT1080 cell line (0.35-2 pglml) to higher levels (1 5 pg/ml) using the HEK293 cell line [ll-131. The advantage of this approach is that the procollagen is secreted into the medium from where it can be purified. The HT1080 cell line has only low levels of proteinase activity in the medium so most of the secreted material is procollagen, whereas HEK293 cells do contain a protease activity that cleaves the C-propeptide [14] . The material secreted from mammalian cell lines can be purified and used to form ordered fibrils in vitro by the addition of the C-and N-proteinases [lS] . A summary of the various expression systems and their advantages and disadvantages is presented in Table 1 .
One of the most promising mammalian expression systems to date is that which utilizes the mammary gland as a bioreactor [16]. Human proteins destined for clinical use have been produced in biologically active form by expression in the milk of transgenic animals. This system utilizes either genomic inserts or cDNA transgene sequences in conjunction with mammary glandspecific promoters to drive expression of proteins in milk. The use of genomic constructs generally results in relatively high expression levels ( 3 1 mg/ml) and yields of up to 33 mg/ml have In order to test the mammary gland expression system for the synthesis of procollagens we generated several mouse lines expressing a recombinant chimaeric procollagen molecule, corresponding to an engineered proa2( I) chain. Mouse lines were generated by integration of cDNA coding for this molecule into the mouse genome using a vector designed to express cDNA constructs in milk. Transgenic lines were established containing cDNAs encoding the a-and /3-subunits of P4H together with the truncated procollagen. We have shown that up to 200 pg/ml of recombinant procollagen was produced in mouse milk and that the protein was expressed as disulphidelinked trimers containing a thermostable triplehelical domain [ 191.
Summary
The complex nature of the biosynthesis of collagen makes it a challenging protein to express in recombinant form. The requirement for the posttranslational modification of proline to form hydroxyproline is the major consideration when choosing a host to produce collagen. Co-expression of P4H in host cells lacking this enzyme has resulted in the production of correctly folded collagen that can be used as a substitute for collagen extracted from tissues. Novel engineered collagens have also been produced using either mammalian cell-lines or transgenic animals. In the future these recombinant proteins will be used both to investigate the molecular basis and biochemistry of collagen assembly and to produce collagens with new pharmaceutical and medical uses.
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